Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma
Prognostic Implication of Histopathologic Indicators in Salivary Duct Carcinoma
复制标题
唾液管癌组织病理学指标的预后意义
DOI:
10.1097/pas.0000000000001413
复制
发表时间:
2020
期刊:
影响因子:
--
通讯作者:
Nagao Toshitaka et al.
中科院分区:
文献类型:
--
作者:
Nakaguro Masato;Sato Yukiko;Tada Yuichiro;Kawakita Daisuke;Nagao Toshitaka et al.
Salivary duct carcinoma (SDC) is a rare, aggressive malignancy that histologically resembles high-grade mammary duct carcinoma. Because of the rarity of this entity, data verifying the association between histologic features and patient survival are limited. We conducted a comprehensive histologic review of 151 SDC cases and performed an analysis of the association between various histomorphologic parameters and the clinical outcome with the aim of developing a histologic risk stratification model that predicts the prognosis of SDC patients. A multivariate analysis revealed that prominent nuclear pleomorphism (overall survival [OS]: P= 0.013; progression-free survival [PFS]: P= 0.019),≥ 30 mitoses/10 HPF (PFS: P= 0.013), high tumor budding (OS: P= 0.011; PFS: P< 0.001), and high poorly differentiated clusters (OS: P< 0.001; PFS: P< 0.001) were independent prognostic factors. Patients with vascular invasion demonstrated a marginally significant association with shorter PFS (P= 0.064) in a multivariate analysis. We proposed a 3-tier histologic risk stratification model based on the total number of positive factors among 4 prognostically relevant parameters (prominent nuclear pleomorphism,≥ 30 mitoses/10 HPF, vascular invasion, and high poorly differentiated clusters). The OS and PFS of patients with low-risk (0 to 1 point)(23% of cases), intermediate-risk (2 to 3 points)(54% of cases), and high-risk (4 points)(23% of cases) tumors progressively deteriorated in this order (hazard ratio, 2.13 and 2.28, and 4.99 and 4.50, respectively; P trend< 0.001). Our histologic risk stratification model could effectively predict patient survival and may be a useful aid to guide clinical decision-making in relation to the management of patients with SDC.